Emyria Ltd (ASX: EMD) Share Price and News

Sir Tooke is Chairman of Academic Health Solutions, a start-up Group offering expert advice to clients internationally on medical research and innovation strategy and health service transformation. He is Senior Independent Director at BUPA Chile and was until 2019 non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council. Sir John was Head of the School of Life and Medical Sciences at University College London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 - 2015. He is the Past President of the Academy of Medical Sciences in the UK Sir John is a clinician scientist with 30 years of experience as a consultant physician specializing in diabetes, endocrinology, vascular medicine and internal medicine with research experience (basic biomedical, experimental medicine, and applied health research including improvement science).

Mr Winlo, prior Emyria, Michael was CEO and a Director at Linear Clinical Research Ltd (Linear) providing clinical trial services for US - and Asia based biotech companies. Linear was the first site in Australia and one of only a few in the world to adopt electronic data capture technology. Prior to Linear, Michael was Health Lead at Palantir Technologies - a Big Data company based in Silicon Valley California.

Ms Smith's experience covers 100+ clinical trials and 20+ regulatory approvals in multiple jurisdictions including FDA (USA), EMA (Europe), TGA (Australia), ANVISA (Brazil), and PMDA (Japan); leading to product launches across diverse therapeutic areas including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox, Aczone), neuroscience (Abilify, Solriamfetol), and anti-infectives (Teflaro). In addition to growth and creation of R&D pipelines, Dr Smith's record of business development includes acquisitions, divestitures, and partnership deals. Dr. Smith has held various executive roles over the past 20 years, including President, CEO, Global Head of R&D, and Chief Medical Officer. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca, and Bristol Myers Squibb. Dr. Smith currently serves on the Board of Sangamo Therapeutics (SGMO), Skye Therapeutics (SKYE), and Context Therapeutics (CNTX).

Dr Kaushal provides strategic support and advice to the firm's investment teams and portfolio companies in the Healthcare sector, drawing on his career in investing, clinical medicine, academia, and public policy. Mohit served as a member of the White House Health IT task force during the Obama Administration and built and led the healthcare team at the Federal Communications Commission. He served on the Food and Drug Administration Safety and Innovation Act Workgroup of the Health IT Policy Committee and the National Committee on Vital and Health Statistics, advising Health and Human Services on data access and use. Mohit is also an ER physician, an Adjunct Professor of Biomedical Data Science at Stanford University and continues to be active within public policy as a Scholar in Residence at the newly created Duke Margolis Center for Health Policy. Earlier in his career, he was a Visiting Scholar at the Brookings Institution.

Mr Hutchinson's professional background includes founding, commercializing and scaling of innovative clinical delivery care models. Mr. Hutchinson has held leadership roles in rapidly scaling clinical services delivery for over 30 years, including 15 years in his immediate past role as the CEO of Sonic HealthPlus. Mr Hutchinson co-founded and is a director of 5D Clinics, a national radiation oncology business specializing in radiosurgical treatment using CyberKnife technology.

-

-

-

-

-

-

-

-

-

-

-